Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a ...

plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease (CD), fistulising Crohn’s disease and ulcerative colitis (UC). Remsima ® SC is a subcutaneous version of Celltrion’s ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

and plaque psoriasis. Globally, infliximab (including biosimilars) generated approximately $6.3 billion in sales in 2022, demonstrating the significant market for this therapy. However ...